- Home
- PRFX vs ALLR Comparison
PRFX vs ALLR Comparison
Compare PRFX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- ALLR
- Stock Information
- Founded
- PRFX 2007
- ALLR 2004
- Country
- PRFX Israel
- ALLR United States
- Employees
- PRFX N/A
- ALLR N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- ALLR Health Care
- Exchange
- PRFX Nasdaq
- ALLR Nasdaq
- Market Cap
- PRFX 3.6M
- ALLR 4.0M
- IPO Year
- PRFX 2020
- ALLR N/A
- Fundamental
- Price
- PRFX $2.06
- ALLR $0.85
- Analyst Decision
- PRFX Hold
- ALLR
- Analyst Count
- PRFX 1
- ALLR 0
- Target Price
- PRFX N/A
- ALLR N/A
- AVG Volume (30 Days)
- PRFX 55.9K
- ALLR 564.6K
- Earning Date
- PRFX 06-20-2025
- ALLR 08-04-2025
- Dividend Yield
- PRFX N/A
- ALLR N/A
- EPS Growth
- PRFX N/A
- ALLR N/A
- EPS
- PRFX N/A
- ALLR N/A
- Revenue
- PRFX N/A
- ALLR N/A
- Revenue This Year
- PRFX N/A
- ALLR N/A
- Revenue Next Year
- PRFX N/A
- ALLR N/A
- P/E Ratio
- PRFX N/A
- ALLR N/A
- Revenue Growth
- PRFX N/A
- ALLR N/A
- 52 Week Low
- PRFX $1.68
- ALLR $0.61
- 52 Week High
- PRFX $18.17
- ALLR $17.35
- Technical
- Relative Strength Index (RSI)
- PRFX 51.59
- ALLR 39.03
- Support Level
- PRFX $1.93
- ALLR $0.78
- Resistance Level
- PRFX $2.11
- ALLR $0.93
- Average True Range (ATR)
- PRFX 0.10
- ALLR 0.07
- MACD
- PRFX 0.03
- ALLR -0.02
- Stochastic Oscillator
- PRFX 80.77
- ALLR 18.72
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.